Publications
Search our publications, laboratory reports, meeting statements, scheduling submissions and scheduling decisions.
Can't find what you’re looking for? You can also:
- search our Resources
- use the site search bar in the top right of this screen for more results.
Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
Topic
- Committees and advisory bodies (378)
- Scheduling (national classification system) (176)
- Safety monitoring and information (31)
- COVID-19 (11)
- Manufacturing (11)
- Advertising (9)
- Clinical trials (8)
- Medicinal cannabis hub (6)
- Compliance and enforcement (5)
- Fees and payments (5)
- Sunscreens (5)
- Shortages and supply disruptions (4)
- Legislation (3)
- Breast implant hub (1)
- Import and export (1)
- Labelling and packaging (1)
- Metal-on-metal hip replacement implants hub (1)
- Prescription opioids hub (1)
- Unique Device Identification (UDI) hub (1)
Search
773 result(s) found, displaying 151 to 175
-
Corporate reportsThis publication outlines our plan to transition to a paperless model for Special Access Scheme (SAS) and Authorised Prescriber (AP) submissions. From 1 July 2024 we will only accept submissions via the SAS/AP Online System.
-
Meeting statementsAdvisory Committee on Medicines meeting statement
-
Meeting statementsAdvisory Committee on Complementary Medicines meeting statement for 20 April 2023
-
Meeting statementsAdvisory Committee on Complementary Medicines meeting statement for 13 July 2023
-
Meeting statementsAdvisory Committee on Complementary Medicines meeting statement for 9 November 2023
-
Scheduling decisions (final)Final decision on proposed amendments to the Poisons Standard relating to palovarotene
-
Meeting statementsAdvisory Committee on Vaccines meeting statement for meeting 45, held on 4 October 2023.
-
Meeting statementsAdvisory Committee on Vaccines meeting statement for meeting 46, held on 29 November 2023.
-
Meeting statementsAdvisory Committee on Medicines meeting statement
-
Corporate reportsThis report provides information about our regulatory performance from 1 July 2022 to 30 June 2023.
-
Scheduling decisions (final)Read our notice of final decision to amend (or not amend) the current Poisons Standard in relation to bisacodyl, olopatadine and ibotenic acid.
-
Scheduling submissionsFind out about the public submissions on interim decisions for scheduling matters referred to the ACMS #42 and Joint ACMS-ACCS #34 meetings held in June 2023.
-
Meeting statementsRead key points of discussion from the meeting 12 of the Medical Devices Consumer Working Group (MDCWG).
-
Corporate reportsRead our 2023 stakeholder survey report, which aims to improve the way we work with our stakeholders.
-
Corporate reportsWe survey our stakeholders each year to help evaluate our performance and identify ways of improving.
-
Meeting statementsAdvisory Committee on Vaccines meeting statement
-
Meeting statementsRead our Communique from the 5th meeting of the Women's Health Products Working Group (WHPWG), 30 October 2023.
-
Corporate reportsMedical Devices Safety Update (MDSU) provides practical advice and information about medical device safety.
-
Meeting statementsAdvisory Committee on Medicines meeting statement
-
Corporate reportsThe strategy outlines the approach we will use to identify, engage with, and educate stakeholders about regulatory requirements and our compliance outcomes.
-
Meeting statementsCommunique from the 4th meeting of the Women's Health Products Working Group (WHPWG), 31 July 2023
-
Scheduling decisions (final)Read the notice of final decisions to not amend the Poisons Standard in relation to ketamine, esketamine and methysergide
-
Meeting statementsFind out about the AIVC Recommendations for the Composition of Influenza Vaccines for Australia in 2024
-
Scheduling decisions (final)Read the notice of final decisions to not amend the Poisons Standard in relation to comfrey.
-
Meeting statementsAdvisory Committee on Vaccines meeting statement